E
ALGS icon

Ergoteles’s Aligos Therapeutics ALGS Stock Holding History

Ergoteles’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,455
Closed -$34.7K – 1213
2022
Q4 		$34.7K Sell
1,455
-661
-31% -$16.7K ﹤0.01% 1321
2022
Q3 		$58K Sell
2,116
-2,032
-49% -$67.5K ﹤0.01% 1432
2022
Q2 		$125K Buy
+4,148
New +$141K ﹤0.01% 1458

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ergoteles's ALGS Position: Q1 2023 in Review

Ergoteles sold out of Aligos Therapeutics (ALGS) in Q1 2023, closing a stake of 1,455 shares — an estimated $34.7K sold.

Ergoteles first reported a position in ALGS in Q2 2022 and held it in 3 quarters. The position peaked at $125K in Q2 2022. 45 funds tracked by Wall St. Rank hold ALGS as of Q1 2023.

  • Ergoteles reported no remaining Aligos Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 1,455 Aligos Therapeutics shares in Q1 2023, an estimated $34.7K.
  • Ergoteles first reported a position in Aligos Therapeutics in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Aligos Therapeutics position peaked at $125K in Q2 2022.
  • 45 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.